Second Malignant Neoplasms in Operable Carcinoma of the Breast

Holdener, E. E.; Nissen-Meyer, R; Bonadonna, Gianni; Jones, Steven E.; Howell, Anthony; Rubens, R. D.; Senn, Hans

doi:10.1007/978-3-642-82357-2_24

Cited by 27 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports of the classic t-AML syndrome in breast cancer patients were associated with either prolonged alkylating agent exposure andlor radiotherapy, but not with short course CAF-like regimens (Lerner, 1978;Arthur and Bloomfield, 1984;Groupe Franqais, 1984;Holdener et al, 1984;Fisher et al, 1985;Herring et al, 1986;Kantarjian et al, 1986;Le Beau et al, 1986;Henderson and Gelman, 1987;Valagussa et al, 1987;Whang-Peng et al, 1988). Clearly this new variant of t-AML is rare.…”

Section: Discussionmentioning

confidence: 94%

“…Each of the large series of patients with t-MDS/t-AML includes several patients with breast carcinoma who were treated for prolonged durations with chemotherapy with or without radiotherapy (Davis et al, 1973;Rosner et al, 1978;Groupe Franqais, 1984;Michels et al, 1985;Kantarjian et al, 1986;Le Beau et al, 1986;Kantarjian and Keating, 1987; Whang-Peng et al, 1988). However, neither t-MDS nor t-AML have been reported to occur with increased frequency following adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), or cyclophosphamide, doxorubicin (Adriamycin), and 5-fluorouracil (CAF) (Holdener et al, 1984;Herring et al, 1986;Henderson and Gelman, 1987;Valagussa et al, 1987). In contrast, adjuvant therapy with radiotherapy, L-phenylalanine mustard (L-Pam), or chlorambucil has been associated with an increased incidence of t-MDS or t-AML (Lerner, 1978;Fisher et al, 1985).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy‐related monocytic leukemia with a 9;11 translocation

Albain

Beau

Ullirsch

et al. 1990

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

The present case, together with other reports reviewed herein, defines a new subtype of therapy-related acute myeloid leukemia (t-AML). This variant of t-AML is characterized by a short interval from initial drug therapy to bone marrow dysfunction and monocytic morphology without trilineage dysplasia. Unlike classic t-AML, which frequently has abnormalities of chromosomes 5 and/or 7, this new subtype is characterized by rearrangements involving band q23 of chromosome 11, most commonly a 9;11 translocation. The majority of patients with this subtype t-AML had prior cytotoxic therapy with topoisomerase II-reactive drugs including anthracyclines, epipodophyllotoxins, or actinomycin D, combined with either an alkylating agent or cisplatin. This association of prior therapy which includes topoisomerase II-reactive agents and a rapidly appearing t-AML involving the monocytic line and chromosome 11 requires additional study.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy‐related monocytic leukemia with a 9;11 translocation

Albain

Beau

Ullirsch

et al. 1990

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

show abstract

“…The absence of an increased risk of secondary AML in several published reports may be attributable to the relatively small populations studied [37–41]. It is important to note that few patients in these reports received additional anthracyclines and no patient received hematopoietic growth factors.…”

Section: Alkylating Agents (Table 1)mentioning

confidence: 99%

Leukemia Risk after Adjuvant Treatment of Early Breast Cancer

Balduzzi

Castiglione‐Gertsch

2005

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Modern cancer treatment has substantially increased the survival and curability of patients with various malignancies. Therefore, favorable prognosis mandates for the evaluation of long-term complications of treatment. Since the late 1970s, adjuvant combination chemotherapy for operable breast cancer has come into widespread use. Several recent studies have estimated the risk of acute myeloid leukemia associated with these regimens. The purpose of this analysis is to discuss the risk of leukemia after early breast cancer therapy, the types of leukemia, and the relationship between the risk of leukemia and treatment with different cytotoxic agents (alkylating agents, antimetabolities, topoisomerase II inhibitors, dose-dense therapy, high-dose therapy and growth factor use) and radiotherapy.

show abstract

“…Patients with breast cancer who received chemotherapy in the SEER registry and NSAPB trials have been shown to manifest a significantly higher incidence of leukemia than those who underwent surgery alone [50,51]. Reassuringly, however evidence exists to suggest that patients with early breast cancers who have received adjuvant CMF (cyclophosphamide, methotrexate, and fluorouracil) chemotherapy do not suffer from a higher incidence of second cancers [52,53]. The first taxoid to be identified was paclitaxol (taxol) (Fig.…”

Section: Alkylating Agentsmentioning

confidence: 98%

Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer

Smith¹,

Hutcheon²,

Heys

2000

CPD

View full text Add to dashboard Cite

A substantial proportion of breast cancers are large (<3 cm) or locally advanced (T3, T4, TXN2) at the time of initial presentation. The therapeutic goals that must be achieved in patients with such cancers are to obtain adequate local disease control so that surgery can be performed and to abolish occult distant metastases therefore improving survival. Over the past three decades conventional adjuvant chemotherapy regimens have been employed pre-operatively (neo-adjuvant or primary chemotherapy) to achieve these goals. Studies have now shown that the survival of patients who receive neo-adjuvant chemotherapy is comparable to that of those who receive the same chemotherapy regimen following surgery. It is also apparent that although clinical tumour response rates to neo-adjuvant chemotherapy may be high there is considerable scope for improvement in the corresponding pathological tumour response. Furthermore, data from major studies that have comprehensively evaluated the use of pre-operative chemotherapy now indicates that the pathological response of breast cancers following treatment is of far greater prognostic importance than the clinical response. Recent interests has focoused, therefore, on the implementation of more prolonged or dose intensive chemotherapy regimens with the aims of improving pathological response to treatment and ultimately overall survival. Newer antineoplastic agents are also becoming available that may be used alone or in combination with conventional therapies in order that tumor response may be improved. This review describes current and potential therapeutic agents that may be used for the induction therapy of breast cancer.

show abstract

Second Malignant Neoplasms in Operable Carcinoma of the Breast

Cited by 27 publications

References 35 publications

Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy‐related monocytic leukemia with a 9;11 translocation

Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy‐related monocytic leukemia with a 9;11 translocation

Leukemia Risk after Adjuvant Treatment of Early Breast Cancer

Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer

Contact Info

Product

Resources

About